We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
3 result(s) found, displaying 1 to 3
-
Australian public assessment report (AusPar)AusPAR for Tecentriq (atezolizumab) for conversion of provisionally registered indication (for treatment of locally advanced or metastatic triple negative breast cancer (mTNBC)) to full registration (withdrawn).
-
Australian public assessment report (AusPar)New AusPAR for Tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer.
-
Australian public assessment report (AusPar)Australian Public Assessment Report for Bevacizumab